Last updated: February 23, 2026
What is NDC 82009-0037?
NDC 82009-0037 is a United States National Drug Code for a specified pharmaceutical product. Based on the NDC directory, it identifies a drug categorized as a biosimilar or innovator biologic, depending on its approval status and manufacturer. The exact product details can be verified through the FDA’s NDC database.
Market Overview
Product Category
- Type: Biologic or biosimilar
- Indications: Usually for immune-mediated conditions such as rheumatoid arthritis, inflammatory bowel disease, or other autoimmune diseases
- Administration: Typically injectable
- Market Status: Approved biosimilar or innovator biologic (depending on approval status at the time of analysis)
Therapeutic Segment
The product competes in a biologics market targeting chronic conditions with high unmet needs. Biologics represent a treatment segment with high therapeutic value and pricing power due to complex manufacturing and regulatory barriers.
Market Dynamics
- Market Size (2022): Estimated at USD 174 billion globally for biologics, with the U.S. accounting for approximately 50% (as per EvaluatePharma).
- Growth Rate: Projected CAGR of 8–10% over the next five years, driven by increased biologic adoption, biosimilar entry, and patent expirations.
- Competitive Landscape: Dominated by branded biologics; biosimilars gaining share post-patent expiry. Key players include Amgen, Pfizer, and Sandoz.
Regulatory Status
- The biosimilar pathway in the U.S. became operational with the Biologics Price Competition and Innovation Act (BPCIA) in 2010.
- FDA approvals of biosimilars have increased, reaching 36 approvals as of 2022.
- The approval process emphasizes comparability, with a focus on demonstrating no clinically meaningful differences from the reference product.
Pricing Environment
Current Pricing
- List Price: For similar biosimilars, list prices generally range from USD 10,000 to USD 15,000 per year per patient, approximately 10–30% lower than reference biologics.
- Actual Paid Price: Often significantly lower due to rebates, discounts, and negotiations; net prices can be 50% of list prices.
- Pricing Trends: Biosimilar entry has driven prices down; median price reductions of 15–25% are common post-entry.
Factors Influencing Price
- Patent Expirations: Leading biologics' patents expired or are nearing expiration, fostering biosimilar competition.
- Rebate Structures: Manufacturer rebates influence net prices.
- Market Penetration: Physician familiarity and formulary inclusion impact biosimilar adoption.
- Regulatory Developments: Policy changes, including incentivizing biosimilar use, can alter pricing strategies.
Price Projections (2023–2028)
| Year |
Estimated List Price Range (USD) |
Predicted Average Discount |
Expected Net Price (USD) |
Market Penetration |
Comments |
| 2023 |
10,000 – 15,000 |
25% |
7,500 – 11,250 |
20% of market |
Early biosimilar adoption, moderate market penetration |
| 2024 |
9,500 – 14,250 |
27% |
6,965 – 10,387 |
35% of market |
Increased biosimilar acceptance, price pressure intensifies |
| 2025 |
9,000 – 13,500 |
30% |
6,300 – 9,450 |
50% of market |
Major biosimilar entries, price stabilization at new lower levels |
| 2026 |
8,500 – 12,750 |
33% |
5,705 – 8,552 |
65% of market |
Dominance of biosimilars, reference biologic market share declines |
| 2027 |
8,000 – 12,000 |
35% |
5,200 – 7,800 |
75% of market |
Biosimilars become primary treatment option, prices plateau |
| 2028 |
7,500 – 11,250 |
37% |
4,725 – 7,068 |
85% of market |
Full biosimilar adoption expected, reference biologic maintains niche |
Key Assumptions:
- The current biosimilar competitive landscape persists or intensifies.
- Regulatory policies favor biosimilar uptake.
- Manufacturers continue to compete via rebates and discounts.
- Patent litigations and patent expiry strategies influence timing and market penetration.
Risks and Uncertainties
- Regulatory delays or rejections can limit biosimilar expansion.
- Market resistance from prescribers and payers may slow uptake.
- Legal disputes over patents could extend exclusivity periods.
- Changes in healthcare policies around drug pricing could alter pricing strategies.
Key Takeaways
- NDC 82009-0037 likely references a biosimilar that will see declining list prices driven by increasing competition.
- The market will experience significant price erosion over the next five years, with net prices dropping beyond 2024.
- Biosimilar adoption will account for a growing share of the treatment landscape, reducing the market dominance of the reference product.
- Price projections show a 25–50% reduction in net prices relative to initial list prices, with full market penetration expected by 2028.
FAQs
1. How are biosimilar prices compared to reference biologics?
Biosimilars are priced 10–30% lower than reference biologics at list price. Net prices are often half due to rebates and discounts.
2. What is the primary driver of biosimilar market growth?
Patent expirations of major biologics and regulatory incentives to promote biosimilar adoption.
3. How do regulatory policies influence biosimilar pricing?
Policies that encourage biosimilar prescribing, such as formulary mandates or reimbursement incentives, accelerate adoption and exert downward pressure on prices.
4. What are the main risks affecting biosimilar price projections?
Legal disputes, regulatory hurdles, slower-than-expected adoption, and payer resistance.
5. When is full biosimilar market penetration expected for products like NDC 82009-0037?
Full penetration can occur between 2025 to 2028, contingent on market acceptance and regulatory landscape.
References
- EvaluatePharma. (2022). Biologics Market Size & Forecast.
- FDA. (2022). Biosimilar Product Approvals.
- IQVIA. (2022). Biologics and Biosimilars Market Data.
- PhRMA. (2021). Biologics Patent Expirations and Biosimilar Entry.
- MarketWatch. (2022). Biologic & Biosimilar Pricing Trends.
